Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CEO Sells $134,453.76 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total value of $134,453.76. Following the transaction, the chief executive officer now owns 1,283,362 shares of the company’s stock, valued at $4,209,427.36. This represents a 3.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Neuronetics Stock Performance

Neuronetics stock opened at $4.36 on Friday. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.07. The company has a market capitalization of $132.33 million, a price-to-earnings ratio of -3.54 and a beta of 2.17. The stock has a fifty day moving average of $2.20 and a two-hundred day moving average of $1.42. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Institutional Trading of Neuronetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock worth $506,000 after purchasing an additional 8,466 shares during the last quarter. HighTower Advisors LLC boosted its position in Neuronetics by 55.5% during the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after acquiring an additional 87,816 shares during the last quarter. GSA Capital Partners LLP boosted its position in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Neuronetics in the 3rd quarter worth approximately $53,000. Finally, JPMorgan Chase & Co. raised its holdings in Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after acquiring an additional 54,442 shares during the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.